The Dark Side of Ozempic: How Off-Label Use is Reshaping Bodies, Relationships, and Bank Accounts

Two years ago, a woman in her early 30s with no diabetes and a body mass index just shy of the obesity threshold decided to try Ozempic, the blockbuster diabetes drug that had become a viral sensation for its dramatic weight-loss effects. She wasn’t prescribed the medication—she bought it off-label, paying out of pocket as she chased a ‘healthy’ BMI and what she believed would be a more socially acceptable body. Today, her partner describes the transformation as a ‘net negative’: a flat butt, wrinkled skin, lost muscle mass, and a sex life that has dwindled alongside her savings. ‘I am so uncomfortable, and I want to leave,’ the partner wrote anonymously in a viral post. ‘I’m trying not to.’ Their story is one of dozens emerging as Ozempic and similar GLP-1 medications—originally designed for type 2 diabetes management—redefine beauty standards, strain personal relationships, and reshape the financial lives of those who use them without medical supervision.

Why Ozempic Went Viral: From Diabetes Drug to Weight-Loss Phenomenon

Ozempic, generically known as semaglutide, was approved by the U.S. Food and Drug Administration in 2017 as a treatment for type 2 diabetes under the brand name Ozempic. Manufactured by Novo Nordisk, the injectable medication belongs to a class called GLP-1 receptor agonists, which mimic a hormone that regulates blood sugar and appetite. Early clinical trials showed remarkable efficacy: patients on Ozempic lost an average of 15% of their body weight over 68 weeks in a key study. But the drug’s weight-loss potential didn’t remain confined to medical journals. By 2022, celebrity endorsements, TikTok trends, and media coverage had catapulted Ozempic into cultural consciousness as a ‘miracle’ weight-loss solution. Demand skyrocketed. In 2023, Ozempic generated $15 billion in global sales, making it one of the fastest-selling drugs in pharmaceutical history. Yet its off-label use—by people without diabetes or obesity—has sparked a health and ethical debate about the unintended consequences of rapid, medically unsupervised weight loss.

The Rise of GLP-1 Drugs: A Market Transformed

The GLP-1 drug class now includes several competitors, including Wegovy (a higher-dose version of semaglutide approved for chronic weight management in 2021) and Mounjaro (tirzepatide, approved in 2022 for diabetes and under review for weight loss). Novo Nordisk and Eli Lilly, the makers of these drugs, have raced to meet demand, investing billions in manufacturing and supply chain expansion. As of mid-2024, Wegovy is prescribed to over 1 million Americans, while Ozempic sees off-label use by an estimated 2.5 million. The drugs’ popularity reflects deep cultural anxieties about body image, aging, and the relentless pressure to conform to narrow beauty ideals—especially for women. Social media platforms, particularly TikTok and Instagram, are awash with before-and-after posts, transformation timelines, and ‘getting started’ guides, often omitting the risks. ‘This isn’t just about weight loss—it’s about identity, power, and control,’ says Dr. Fatima Cody Stanford, an obesity medicine specialist at Massachusetts General Hospital. ‘When a drug reshapes your body this fast, it changes how you see yourself—and how others see you.’

The Human Cost: Body Dysmorphia, Muscle Loss, and Eating Disorders

The most visible consequence of rapid weight loss on Ozempic is often aesthetic: sagging skin, hollow cheeks, and a pronounced gauntness that can make individuals appear older or malnourished. But beneath the surface, the drug accelerates muscle catabolism—breaking down lean tissue at a rate faster than the body can rebuild it. ‘Patients on GLP-1 drugs often lose 30–40% of their weight as fat-free mass, which includes muscle and bone density,’ explains Dr. Diana Thiara, medical director of the UCSF Weight Management Program. ‘That’s why we recommend resistance training and protein supplementation alongside these medications.’ The loss of muscle mass can lead to weakness, balance issues, and even osteoporosis in the long term.

A Partner’s Perspective: Intimacy, Appearance, and Unmet Expectations

The anonymous partner’s account is not isolated. In online forums, Reddit threads, and support groups, partners of Ozempic users describe similar transformations: once athletic bodies reduced to skeletal frames, confidence replaced by anxiety, and relationships strained by changing dynamics. One Reddit user wrote, ‘My wife started Ozempic a year ago. She went from curvy to ‘waif’ in six months. She’s proud of her BMI, but our intimacy has vanished. I miss the body I fell in love with.’ Another shared, ‘She looks like she’s 80. Her skin is crepey, her eyes are sunken. She says she feels ‘light,’ but I feel like I’m with a stranger.’ These aren’t isolated cases. A 2023 survey by the Obesity Action Coalition found that 42% of respondents using GLP-1 drugs reported dissatisfaction with their appearance post-weight loss, citing ‘unexpected changes’ like sagging skin or muscle loss as primary concerns.

The Shadow of Disordered Eating: When Weight Loss Becomes an Addiction

Weight loss, even when medically supervised, can trigger or unmask eating disorders. But when driven by off-label drug use, the risk intensifies. ‘GLP-1 drugs suppress appetite, but they don’t address the psychological drivers of disordered eating,’ says Dr. Jennifer Gaudiani, founder of the Gaudiani Clinic and author of *Sick Enough: A Guide to the Medical Complications of Eating Disorders*. ‘If someone is predisposed to perfectionism or control issues, these drugs can become a tool for extreme restriction.’ One woman, who lost 111 pounds in 11 months on Ozempic while maintaining a six-figure salary, described her experience in a now-viral TikTok: ‘I weighed myself 10 times a day. I’d eat a handful of almonds, then sprint on the treadmill until I burned off the calories. I passed out in the hallway with my 18-month-old son in the house. My husband said he could feel my ribs during sex. I thought I looked amazing. Now, I can’t stop crying.’

Financial Strain: The Hidden Price of Off-Label Weight Loss

Ozempic’s list price hovers around $1,000 per month without insurance. For the uninsured or those seeking the drug for off-label use, the cost is prohibitive. A 2024 analysis by GoodRx found that the average cash price for a 30-day supply of Ozempic is $969, while Wegovy averages $1,349. Many users turn to compounded versions, which may be unregulated and carry higher risks of contamination or inconsistent dosing. The financial burden is compounded by the drug’s side effects, which often require additional spending on skincare, supplements, or therapy. ‘I was putting $1,200 a month toward Ozempic for two years,’ says a 34-year-old marketing director in Chicago. ‘Now I’m playing whack-a-mole with bills. My credit card debt is higher than my student loans.’ Even those with insurance face hurdles: prior authorization requirements, step therapy policies, and caps on coverage often force patients to switch medications or go without.

Medical Ethics and the Off-Label Dilemma: Who Should Use GLP-1 Drugs?

The FDA does not regulate how doctors prescribe medications—only how they’re marketed. This means physicians can legally prescribe Ozempic for weight loss even in patients with a BMI under 30, as long as they document the decision. But ethicists argue that off-label use for cosmetic weight loss raises serious concerns. ‘We’re medicalizing normal human variation,’ says Dr. Yoni Freedhoff, medical director of the Bariatric Medical Institute in Ottawa. ‘GLP-1 drugs are powerful tools for people with obesity and diabetes, but using them to chase a culturally constructed ideal of thinness is ethically fraught.’ The debate intensifies as new GLP-1 drugs, like Zepbound (tirzepatide for weight loss), enter the market with direct-to-consumer advertising campaigns. ‘The pharmaceutical industry profits from insecurity,’ adds Dr. Freedhoff. ‘And we’re all paying the price.’

Expert Recommendations: How to Use GLP-1 Drugs Safely (If At All)

Healthcare providers emphasize that GLP-1 drugs are not magic bullets and should be used under strict medical supervision. The American Society for Nutrition recommends that patients considering these drugs undergo a comprehensive evaluation, including screening for eating disorders, depression, and muscle-wasting risks. ‘We tell patients: if you’re going to do this, commit to resistance training, increase your protein intake, and monitor your bone density,’ says Dr. Stanford. ‘And for God’s sake, don’t stop the gym.’ Experts also urge caution with compounded versions, which are not FDA-approved and may contain impurities. ‘The black market for GLP-1 drugs is exploding,’ says Dr. Thiara. ‘People are buying injections online without knowing the dose or source. That’s a recipe for disaster.’

Key Takeaways

• Ozempic and similar GLP-1 drugs were designed for diabetes and obesity, but off-label use for cosmetic weight loss has surged, driven by social media and cultural pressure to be thin.
• Rapid weight loss on these drugs can lead to muscle loss, sagging skin, bone density reduction, and psychological distress, including body dysmorphia and eating disorders.
• Partners and loved ones report strained relationships, diminished intimacy, and discomfort with the physical changes in their significant others.
• The financial cost is substantial, with cash prices exceeding $1,000 per month for many users, often leading to debt and financial strain.
• Medical professionals warn that off-label use without supervision can be dangerous, with compounded versions posing additional health risks.

The Bigger Picture: A Cultural Obsession with Thinness

The Ozempic phenomenon is a symptom of a larger cultural crisis: the relentless pursuit of thinness at any cost. The diet industry, worth $71 billion in the U.S. alone, has long profited from insecurity. But GLP-1 drugs represent a new frontier—medicalizing what was once considered a lifestyle choice. ‘We’re seeing a shift from ‘diet culture’ to ‘pharma culture,’’ says Virgie Tovar, a body-positivity activist and author of *You Have the Right to Remain Fat*. ‘Now, thinness isn’t just aspirational—it’s medicalized. And that’s dangerous.’ The FDA’s approval of Wegovy for chronic weight management in 2021, despite its side effects, signals a normalization of drug-based thinness. Meanwhile, the backlash is growing. In 2023, the World Health Organization warned that ‘rapid, medically unsupervised weight loss can lead to long-term health complications.’ Yet the trend shows no signs of slowing down.

What’s Next for GLP-1 Drugs and Weight Loss Culture?

As the GLP-1 market expands, so do the questions. Will insurers cover these drugs for cosmetic use? Will regulators step in to restrict off-label prescribing? And perhaps most importantly, will the cultural obsession with thinness ever wane? Novo Nordisk and Eli Lilly are investing heavily in new formulations, including oral versions and longer-acting injections, to meet demand. But the ethical and health implications remain unresolved. ‘We’re in uncharted territory,’ says Dr. Gaudiani. ‘The genie is out of the bottle. Now, we have to figure out how to put it back in—safely.’